Note that J&J/Bayer's Xarelto (Rivaroxaban) RECORD -1,2, & 3 (hip and knee) studies, in which Xarelto showed superiority over Lovenox, were head-to-head with Lovenox 40mg QD, while RECORD-4 (after total knee replacement operation) was vs. Lovenox 30mg BID.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.